» Articles » PMID: 24363506

How Antibiotic Resistances Could Change Helicobacter Pylori Treatment: A Matter of Geography?

Overview
Specialty Gastroenterology
Date 2013 Dec 24
PMID 24363506
Citations 54
Authors
Affiliations
Soon will be listed here.
Abstract

Therapeutic management of Helicobacter pylori (H. pylori) remains an unsolved issue. Indeed, no therapeutic regimen is able to cure the infection in all treated patients, and in many the infection persists despite the administration of several consecutive standard therapies. Although antibiotic resistance reports describe alarming results, the outcome of therapeutic regimens does not seem to parallel this scenario in most cases, since a successful performance is often reached in more than 80% of cases. However, the phenomenon of increasing antibiotic resistance is being closely studied, and the results show controversial aspects even in the same geographic area. For the continents of Europe, America, Asia, Africa, and Oceania, minimal and maximal values of resistance to the main antibiotics (clarithromycin, amoxicillin, metronidazole, and levofloxacin) feature wide ranges in different countries. The real enigma is therefore linked to the several different therapeutic regimens, which show results that often do not parallel the in vitro findings even in the same areas. A first aspect to be emphasized is that some regimens are limited by their use in very small geographic districts. Moreover, not all therapeutic trials have considered bacterial and host factors affecting the therapeutic outcome. The additional use of probiotics may help to reduce adverse events, but their therapeutic impact is doubtful. In conclusion, the "ideal therapy", paradoxically, appears to be a "utopia", despite the unprecedented volume of studies in the field and the real breakthrough in medical practice made by the discovery and treatment of H. pylori. The ample discrepancies observed in the different areas do not encourage the development of therapeutic guidelines that could be valid worldwide. On these bases, one of the main challenges for the future might be identifying a successful solution to overcome antibiotic resistances. In this context, geography must be considered a relevant matter.

Citing Articles

Review of Methods for Detection in Kazakhstan.

Alyona L, Aizhan S, Aidana T, Alexey S, Yekaterina Y JGH Open. 2025; 9(1):e70101.

PMID: 39830988 PMC: 11740085. DOI: 10.1002/jgh3.70101.


Experience of Metronidazole Triple Therapy After Clarithromycin Triple Therapy Failure for Eradication in Korea.

Lee C, Kim S, Choi J, Cho H, Lee O J Clin Med. 2025; 13(24.

PMID: 39768580 PMC: 11678454. DOI: 10.3390/jcm13247658.


: Routes of Infection, Antimicrobial Resistance, and Alternative Therapies as a Means to Develop Infection Control.

Elbehiry A, Abalkhail A, Anajirih N, Alkhamisi F, Aldamegh M, Alramzi A Diseases. 2024; 12(12.

PMID: 39727641 PMC: 11727528. DOI: 10.3390/diseases12120311.


Role of MIC levels and 23S rRNA mutation sites to clarithromycin in 14-day clarithromycin bismuth quadruple therapy for eradication: A prospective trial in Beijing.

Chen Y, Li S, Li W, Wang Y, Shi J, Xu X Heliyon. 2024; 10(8):e29774.

PMID: 38699713 PMC: 11063421. DOI: 10.1016/j.heliyon.2024.e29774.


The Anti-Helicobacter pylori effects of Limosilactobacillus reuteri strain 2892 isolated from Camel milk in C57BL/6 mice.

Nia F, Rahmati A, Ariamanesh M, Saeidi J, Ghasemi A, Mohtashami M World J Microbiol Biotechnol. 2023; 39(5):119.

PMID: 36918449 DOI: 10.1007/s11274-023-03555-x.


References
1.
Etukudo O, Ikpeme E, Ekanem E . Seroepidemiology of Helicobacter pylori infection among children seen in a tertiary hospital in Uyo, southern Nigeria. Pan Afr Med J. 2012; 12:39. PMC: 3415059. View

2.
Rosania R, Minenna M, Giorgio F, Facciorusso A, De Francesco V, Hassan C . Probiotic multistrain treatment may eradicate Helicobacter pylori from the stomach of dyspeptics: a placebo-controlled pilot study. Inflamm Allergy Drug Targets. 2012; 11(3):244-9. DOI: 10.2174/187152812800392698. View

3.
Alarcon T, de la Obra P, Domingo D, Garcia-Campos J, Diaz-Reganon J, Lopez-Brea M . [In vitro activity of furazolidone and nitrofurantoin in Helicobacter pylori clinical isolates and study of mutation rate]. Rev Esp Quimioter. 2006; 18(4):313-8. View

4.
Drlica K, Zhao X . DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev. 1997; 61(3):377-92. PMC: 232616. DOI: 10.1128/mmbr.61.3.377-392.1997. View

5.
Loffeld R, Werdmuller B . Changes in Antibiotic Susceptibility of Helicobacter pylori in the Course of Eight Years in the Zaanstreek Region in The Netherlands. Gastroenterol Res Pract. 2013; 2013:625937. PMC: 3610376. DOI: 10.1155/2013/625937. View